Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00093080
Status:
COMPLETED
Last Update Posted:
2015-02-13
First Post:
2004-09-30
Brief Title:
Study of AP23573MK-8669 Ridaforolimus A Mammalian Target of Rapamycin mTOR Inhibitor in Participants With Advanced Sarcoma MK-8669-018 AM1COMPLETED
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Phase II Study of AP23573 An mTOR Inhibitor in Patients With Advanced Sarcoma
Status:
COMPLETED
Status Verified Date:
2015-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the efficacy of ridaforolimus when administered once daily for 5 consecutive days QDx5 every two weeks in participants with advanced sarcoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004-002231-92 | EUDRACT_NUMBER | Ariad Pharmaceuticals Inc | None |
| AP23573-04-202 | OTHER | None | None |